Zusammenfassung
Vardenafil, a phosphodiesterase-5 inhibitor, is approved for the therapy of erectile dysfunction. However, in contrast to Sildenafil and Tadalafil, little is known about its effects on pulmonary hypertension. Four weeks after monocrotaline-administration rats exhibited a significant increase in right ventricular pressure (RVSP, 94 mmHg vs. 25 mmHg; p =0.001) right ventricular weight (right ...
Zusammenfassung
Vardenafil, a phosphodiesterase-5 inhibitor, is approved for the therapy of erectile dysfunction. However, in contrast to Sildenafil and Tadalafil, little is known about its effects on pulmonary hypertension. Four weeks after monocrotaline-administration rats exhibited a significant increase in right ventricular pressure (RVSP, 94 mmHg vs. 25 mmHg; p =0.001) right ventricular weight (right ventricle/left ventricle + septum, 59 vs. 23; p =0.001) and pulmonary vascular remodeling (medial wall area 104% vs. 66%; p < 0.05) as compared to controls, with a corresponding reduction in exercise capacity (% from baseline value: 67%; p <0.05). Vardenafil treatment resulted in decreased RVSP (56 mmHg vs. 95 mmHg; p = 0.008), right ventricular weight (41 vs. 59; p = 0.013), pulmonary vascular remodeling (medial wall area 64% vs. 104%; p <0.05) and a significant better exercise capacity (% from baseline value: 84% vs. 67%; p <0.05) compared to monocrotaline only treated animals. In conclusion, Vardenafil exerts beneficial effects on monocrotaline-induced pulmonary hypertension in rats. Whether it is a treatment option for patients with pulmonary hypertension needs to be elucidated. (C) 2012 Elsevier B.V. All rights reserved.
Altmetric